Let's Get Started

COVID-19

Adagio Therapeutics ADGI Stock Price is consolidated and ready for a run? URGENT Report

Mar 30, 2022

ADGI Stock Price has been trying to recover since it’s all-time high of almost $60. Wondering why this stock is having such a hard time and if it can break the overall trend?

If it went back to that PPS then that is 1,000% ++ gains, but can it?

Before we go over my opinion, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks! 👇 It’s free!


[thrive_leads id=’14274′]

Before we get started, I wanted to introduce myself to you. Hi 🙋‍♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.

I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.

What do I mean by big winners?

Stocks that move more than 100% in a month! ADGI Stock Price could?

Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!

The article is HERE where I shine a spotlight on trending stocks and breakout stocks!

Now, let’s go over some of the basic information on this stock before we get in the technical analysis

Adagio Therapeutics Company Information

Company Name: Adagio Therapeutics Inc.

Ticker: ADGI

Exchange: NASDAQ

Website: https://adagiotx.com/

Adagio Therapeutics Company Summary:

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential.

The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses.

It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses.

The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

ADGI stock price is due to News?

March 30, 2022

Reported that the primary endpoints were met with statistical significance for all three indications in the company’s ongoing global Phase 2/3 clinical trials evaluating its investigational drug adintrevimab (ADG20) as a pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19.

EVADE and STAMP were primarily conducted during a time when pre-Omicron SARS-CoV-2 variants were dominant.

Following the emergence of the Omicron variant, in a pre-specified exploratory analysis in a subset of the pre-exposure cohort, a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab compared to placebo.

Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo.

Based on these data, Adagio plans to engage with the U.S. Food and Drug Administration (FDA) and to submit an Emergency Use Authorization (EUA) application in the second quarter of 2022 for adintrevimab for both the prevention and treatment of COVID-19.

ADGI 5 Day Chart

ADGI Stock Price Technical Analysis:

I absolutely love it! I like it a $5.35 with a stop loss at $5.20. The news is incredible. The chart looks like it has infinite upside potential with the all-time high at $60 providing 1,000% gain potential.

Sign up below, I’m good at what I do and it’s free. 👇💎🚀


[thrive_leads id=’14274′]

read more

Update: iSpecimen ISPC Bottom or Fake out?

Jan 20, 2022

iSpecimen ISPC ran over 200% after our alert on November 22nd but as expected after an epic run like that, it will pull back. Since that 200% gain, ISPC has retraced to $5.39 just $.50 higher than what is was trading before the November explosion. It is official iSpecimen has fully retraced and could be ready for it’s next move up.

However, before you read this insightful information, sign up below, let’s stay in contact.

ISPC

iSpecimen ISPC announced last week, “the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants.” However, before we get started, let’s review some basic information on this company.

iSpecimen Company Summary

Company Name:  iSpecimen

Ticker: ISPC

Exchange: NASDAQ

Website: https://www.ispecimen.com/

ISPC Company Summary

iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. 

LVGI News

Jan. 13, 2022

Announced the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants.

The reference lab, a recent addition to the iSpecimen supplier network, has the capacity to sequence hundreds of COVID-19 positive swabs per week, providing data that is crucial in the fight against the virus. This lab is sequencing the most recent swabs to identify new variants of COVID-19 as the virus continues to progress globally.

ISPC 1 Month Chart

ispc

iSpecimen 5 Day Chart

ISPC

ISPC Technical Analysis

ISPC needs to stay above $5.43 and new highs to be a bounce. If it doesn’t, it will be a head fake! It has consolidated and appears to be slightly bullish. This could be what we have been waiting for!

Remember, to never try and catch a falling safe, or a knife for that matter. Simply let it fall to the ground, walk over, and pick up the money and walk away. If you enjoyed this article, sign up below, I promise I will never spam you and I’m pretty darn good at picking winners. Let’s make some trades together!

ISPC

read more

Wynn Macau WYNMF explode Friday!

Jan 17, 2022

Wynn Macau WYNMF is up big after positive news in regard to Covid that has been making the stock crashing for over the last 12 months. I have written a full report on on WYNMF that you can read below.

However, before you read this insightful information, sign up below, let’s stay in contact.

Wynn Macau WYNMF

Wynn Macau announced as the government of the world’s largest gambling hub retained the limit on casino licences to six. However, before we get started, let’s review some basic information on this company.

Wynn Macau WYNMF Company Summary

Company Name:  Wynn Macau

Ticker: WYNMF

Exchange: OTC

WYNMF 1 Month Chart

Wynn Macau WYNMF

Wynn Macau Technical Analysis

Wynn Macau announced as the government of the world’s largest gambling hub retained the limit on casino licences to six. Keeping the market competition exactly where it is so they can continue it’s domination. HERE

The stock has hit a 1 month high and has reversed it’s bearish trend, keep an eye on it.

Remember, to never try and catch a falling safe, or a knife for that matter. Simply let it fall to the ground, walk over, and pick up the money and walk away. If you enjoyed this article, sign up below, I promise I will never spam you and I’m pretty darn good at picking winners. Let’s make some trades together!

Wynn Macau WYNMF

read more
Canada Cannabis Stocks

Canada Cannabis Stocks

Jan 17, 2022

Canada Cannabis Stocks could take off with the news that marijuana could protect humans from Covid-19. Let’s take a look at 3 Canadian stocks that should be on every traders radar.

Aurora Cannabis (NASDAQ: ACB)

The $2 billion Aurora Cannabis ACB in recent quarters it has been putting up attractive growth numbers with medical cannabis. In its last fiscal quarter medical cannabis revenue rose 42% year over year, as its international medical cannabis sales boosted growth, soaring 562%.

Aurora’s consumer division is growing too, rising 25% last quarter compared to the same period in the previous year. That division is responsible for things like vapes, edibles and concentrates directly to the customer.

Canada Cannabis Stocks such as ACB are really looking good.

Canopy Growth Corporation (NASDAQ:CGC)

The largest of the Canadian cannabis  stocks, Canopy Growth CGC is worth more than $12 billion.

CGC owns several different brands, and it doesn’t just sell marijuana: the company sells CBD, oil, concentrates and capsules.

CGC established operations and distribution network could serve them well upon a move intothe US market. CGC is just waiting for more favorable regulations.

Canada Cannabis Stocks such as Canopy Growth Corporation should be placed on your watchlist.

Cronos Group (NASDAQ:CRON)

Cronos Group CRON reported the highest revenue growth of any major Canadian cannabis stock last quarter, 133% in the fourth quarter of 2020.

Growth was driven by blockbuster expansion in non-U.S. markets, where sales nearly tripled, going from $4.6 million to $13.5 million year over year.

While growth rates this high are certainly hard to find, CRON stock is by no means priced cheaply, with its $3.65 billion market cap representing a price-sales ratio of about 75.

Canada Cannabis Stocks are on the rise, make sure you follow Cronos Group CRON, Canopy Growth CGC & Aurora Cannabis ACB.

read more
Cannabis Prevented Covid: What Stocks to Follow

Cannabis Prevented Covid: What Stocks to Follow

Jan 13, 2022

We’ve been dealing with Covid-19, it seems like for years and it has impacted almost everyone we know. Some folks have lost income, some have lost the most precious thing, loved ones. Our country is also divided on the basics of this pandemic. However, there might be a light at the end of the tunnel with a surprising,but well known, hero. Marijuana, cannabis, wacky tobacky, whatever you call it is showing clinical research to prevent Covid-19. Cannabis Prevented Covid: what stocks to follow so we can make some money.

Cannabis prevented Covid infection in a study released this week and it has Wall Street in a frenzy! Marijuana stocks have been taking a beating over the last year so this is a much needed clinical research for those cannabis traders.

 

CRBP

 

Cannabis Prevented Covid, now what?

There is an incredible article by Bloomberg, here. As we start looking at the impact of this news, we should start researching Cannabis stocks to see if we can capitalize on this amazing green rush that could take place. Cannabis Prevented Covid: what stocks to follow below.

3 Cannabis Stocks To Watch

1. Ticker Corp Name Exchange: CRBP Corbus Pharmaceuticals Holdings, Inc. OTC

Summary: Corbus is committed to connecting innovation to our purpose of improving lives by developing new medicines that target inflammation, fibrosis, metabolism and immuno-oncology, by building upon our underlying expertise in immunology. Corbus’ current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ.

2. Ticker Corp Name Exchange: CGC Canopy Growth Corp NASDAQ

Summary: Canopy Growth (TSX:WEED, NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. 

Leveraging consumer insights and innovation, we offer product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. 

Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany.

3. Ticker Corp Name Exchange: TLRY Tilray Brands NASDAQ

Summary: Tilray, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing.

Happy trading and enjoy our future articles and breaking alerts by signing up below.

 

CGC

read more
Dais Corp DLYT up over 2,000%

Dais Corp DLYT up over 2,000%

Dec 21, 2021

Company Name: Dais Corporation 

Ticker: (DLYT)

Exchange: OTC

Website: https://daisanalytic.com/

Company Summary:

Dais Corporation is a nanotechnology business producing a versatile platform of nanotechnology membrane materials (called Aqualyte™) addressing evolutionary and disruptive air, energy, and water applications. These proven products are characterized by offering Climate Change emission and energy reductions, longer lifetimes, and competitive pricing in the HVAC, Water, and Energy industries. Current commercial revenues come from selling:

  • Advanced Aqualyte™ nanomaterials to a wide range of OEMs wishing to create new or highly differentiated products which embrace the moisture management features of the product.
  • ConsERV™, a commercially available HVAC engineered energy recovery ventilation system that uses energy in exhaust air to precondition the temperature and moisture content of incoming fresh air. ConsERV™ typically saves energy, reduces CO2 emissions, and allows the overall HVAC system to be safely downsized. ConsERV™ introduces fresh ventilation air, resulting in higher productivity and sharper decision-making skills of building occupants, lowers triggers for allergies and asthma, and offers strong protection against key pathogens, including COVID-19 and most aggressive forms of bacteria.

Why is Dais on a rocket ship?

Nov. 29, 2021 Dais Corporation announced the Company has removed $2.12M of convertible, variable debt from its balance sheet.

3 Month Chart

5 Day Chart

Technical Analysis:

It is Bullish overall but this stock finished bearish and is up over 2,000%++. Be VERY careful and I wouldn’t look at this till it beats $6.20 or it will fall or best case consolidate. 

read more
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announces 2b clinical trials!

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announces 2b clinical trials!

Dec 14, 2021

Company Name: BELLUS Health Inc. 

Ticker: (BLU)

Exchange: NASDAQ

Website:  www.bellushealth.com

Company Summary:

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC and is planning a Phase 3 program that is expected to begin in 2022.

Why did it go up almost 100%?

Link HERE – LAVAL, Quebec, December 13, 2021–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ≤ 0.005) at day 28. BLU-5937 was generally well-tolerated, with low rates of taste-related adverse events reported (≤6.5%) at all doses.

Mr. Roberto Bellini, Chief Executive Officer of BELLUS Health commented, “We are extremely pleased with the compelling topline results from the Phase 2b SOOTHE trial which highlight BLU-5937’s best-in-class potential for the treatment of refractory chronic cough. RCC is a prevalent and growing condition that significantly impacts the quality of life of an estimated 9 million patients in the United States and 9 million patients in Europe.”

5 Day Technical Analysis:

There are a lot of traders at $9.05, so if this stock can beat $9.05 tomorrow, I like it. If not, and I’m thinking it won’t, stay away. Caveat, the news is really good, so I hold out hope, but I don’t like the huge 70% gap up. Happy trading and always play it safe with trailing stops!

read more
Discussing Omicron, Facebook & SAND with Alexander Goldman

Discussing Omicron, Facebook & SAND with Alexander Goldman

Dec 2, 2021

A fireside introduction, without the fire, use your imagination!

I’m not a fortune teller, although I’ve been accused of it, I am a simple man that can read stock charts, read people and read a little of Spanlgish.  My name is Alexander Goldman but my friends call me Alex, let’s discuss the topics of the day.

Omicron, shall we drink?

Since the breakout variant Omicron has dominated the news, the Dow Jones Industrial Average has plummeted 2,000 points in two weeks. This market disturbance represents a 6% correction in just 10 trading days. 

Yesterday Moderna (MRNA) CEO Stephane Bancel told the Financial Times that the company’s current COVID-19 vaccine would likely see a “material drop” in effectiveness against Omicron, but that more data was still needed on the variant.

Let’s have a coffee, maybe with some Jameson Whiskey, & discuss, shall we?

The good news is, there are incredible opportunities in tragedies. Take a look above, remember the late/early spring of 2020? We rang in the New Year with grandiose visions of a Great Gatsby kinda 2020 and then boom, Covid! 

The market overreacted and share prices plummeted, then the market DOUBLED in 18 months. The truth is, I’m not drinking because of sorrow, I’m celebrating the opportunities on the horizon. 

Remember the song Gangster’s paradise by Coolio? Well, a trader’s paradise is volatility! Shorters went nuts in the winter of 2020 & the longs went bananas in the Spring. So, everyone come the fu@k down and double dip for god’s sake. Play the short and play the long and then go play some golf.

META, the social media giant formerly known as Facebook

Today Reuters writes, “Facebook risks missing the point of metaverse – and a coming shift in consumers’ behaviour – if it fails to permit digital ownership, according to some of the virtual world’s pioneers.

The social media giant (FB.O) made waves last month by changing its name to Meta Platforms and announcing a focus on the buzzy “metaverse”.

However, with few details beyond the rebrand, metaverse participants doubt it is ready to embrace the spirit driving creativity and profit in the space.

“What Facebook is doing with meta…is a ‘fake metaverse,’ unless they actually have a real description as to how we can truly own it,” said Yat Siu, chairman and co-founder of Animoca Brands, an investor in and builder of metaverse platforms, speaking on a panel at the Reuters Next conference.”

Haters are gonna hate & ainters are gonna aint, shall we discuss?

Is Yat Siu hating? Time will tell. On one hand, it’s Facebook and let’s face it, we might not like it, but they are profit geniuses. On the other hand, they became a juggernaut on the back of monetizing consumer data & being accused of centralizing political power, not decentralizing the power structure which the crypto/metaverse gang preaches. Can FB truly embrace decentralization in the name of profit, we will see. 

Don’t bring SAND to the beach, what about a META beach?

What is SAND.X? 

Truth be told, I didn’t know anything about SAND until I reached out to a trusted advisor about the MetaVerse and I asked, “If you were to invest in the meta verse? How and where?” He responds, “SAND”

I proceeded to research this stock called SAND and to my surprise, I couldn’t find it on the OTC, NASDAQ or Big Board! Do you know why? It’s a cryptocurrency and I got excited! Admit it, everyone who didn’t invest in Bitcoin a few years ago feels like they missed THE boat, and I feel the same way. So, SAND feels like a do over, another chance at Bitcoin. 

As my Ex Girlfriend used to say, We OOOOOO!

Is it too late?

Emma Newberry writes for Motley Fool and she alludes to it here, “there’s a lot of uncertainty about how the metaverse will develop and whether Sandbox can maintain that price.”

That is the 7 day chart ^ and it would appear that she is right, or is she?

Tune in next week to hear a stock trader’s opinion on the SAND chart, by the way I don’t know shit about crypto currencies!

read more
Winners and Losers: PTPI, MTTR, and NRXP

Winners and Losers: PTPI, MTTR, and NRXP

Nov 30, 2021

Company Name: Petros Pharmaceuticals, Inc.

Ticker: PTPI

Exchange: NASDAQ

Website: https://www.petrospharma.com/

Industry: Health & Wellness 

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health and substance use disorders.

Why is it so Bullish?

Nov. 30, 2021 Petros Pharmaceuticals announces that it has entered into definitive agreements with the company’s largest investor and other existing investors, for the purchase and sale of 3,333,333 shares of Petros Pharmaceuticals’ common stock, at a purchase price of $3.00 per share. The company will sell 2,153,333 shares in a registered direct offering and the remaining 1,180,000 shares will be sold in a private placement. Petros Pharmaceuticals has also agreed to issue the investors unregistered warrants to acquire 2,500,000 shares of common stock at an exercise price of $3.50 per share, exercisable immediately and terminating 5 years after the date of issuance. The closing of the offering is expected to occur on or about December 2, 2021, subject to the satisfaction of customary closing conditions.

1 Day Chart 

Technical Summary

Based on the 5 day chart and 1 day chart, I would consider this a bearish trend and would AGAIN, wait for confirmations of a reversal before considering a purchase. NOTE, the 1 month looks interesting but again the short term charts are bearish. 

—————————————————————————————————–

Company Name: Matterport, Inc. 

Ticker: (MTTR)

Exchange: NASDAQ

Website: https://matterport.com/

Industry: Tech  

Company Summary:

Matterport, Inc. (Nasdaq: MTTR) is leading the digital transformation of the built world. Our groundbreaking spatial data platform turns buildings into data to make nearly every space more valuable and accessible. Millions of buildings in more than 150 countries have been transformed into immersive Matterport digital twins to improve every part of the building lifecycle from planning, construction, and operations to documentation, appraisal and marketing.

Why is it so Bullish?

On Nov. 23, 2021 Matterport announced another expansion of Matterport Capture Services™ On-Demand that adds 16 U.S. cities and 20 in Great Britain to its service map, increasing its regional coverage by 55 percent.

5 Day Chart

Technical Summary

Love this stock, it is very bullish and has great news announced today, see below.

Nov. 30, 2021, Matterport introduced Matterport BIM file, a new add-on service that dramatically decreases the time and costs of Building Information Modeling (BIM) for the Architecture, Engineering, and Construction (AEC) industry. Now included with a Matterport subscription, customers can quickly transform a Matterport digital twin captured by a compatible 3D camera into a ready-to-use BIM file at the click of a button. The output is delivered in days, ready to be brought into their BIM application of choice. This new service significantly expedites projects and reduces associated costs by up to 70%, eliminating the traditional manual process that requires considerable time and effort.

—————————————————————————————————–

Company Name: NRx Pharmaceuticals, Inc. 

Ticker: (NRXP)

Exchange: NASDAQ

Website: www.nrxpharma.com 

Industry: Medical

Company Summary:

NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients. The Company is developing the BriLife® Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense. NRx is additionally developing ZYESAMI® (aviptadil) for patients with COVID-19, and has been granted Fast Track designation by the US Food and Drug Administration (FDA), and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022.

Why is it so Bullish?

Nov. 29, 2021 NRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.

1 Day Chart 

Technical Summary:

Another Covid stock, another overbought play that could be a winner but we need confirmation and understanding that it will be volatile. 

read more